Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
Journal of Experimental & Clinical Cancer Research : CR|August 4, 2001
Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot studyN Isambert, M Correia, J P Cercueil, et al.
Bulletin Du Cancer|October 1, 1996
[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin]B Coudert, C De Gislain, J L Beltramo, et al.
European Journal of Cancer Care|May 8, 2013
Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based studyT S Dabakuyo, A Arnaud, P Maingon, et al.
Revue Scientifique Et Technique (International Office of Epizootics)|September 1, 1994
Selection of European Union standard reference sera for use in the serological diagnosis of infectious bovine rhinotracheitisB Perrin, T Calvo, P Cordioli, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 23, 2020
Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancerC-G Kaderbhaï, B Coudert, A Bertaut, et al.
British Journal of Cancer|October 28, 2010
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancerS Guiu, M Gauthier, B Coudert, et al.
Annales De Biologie Clinique|April 9, 2002
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]J M Riedinger, N Eche, J P Basuyau, et al.
Breast Cancer Research and Treatment|November 4, 2016
Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysisClémentine Jankowski, S Guiu, M Cortet, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2012
Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matchingI Le Ray, S Dabakuyo, G Crehange, et al.
British Journal of Cancer|January 13, 2006
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?L Arnould, M Gelly, F Penault-Llorca, et al.
Pageof 9